U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.